Targeted next-generation sequencing for the detection of cancer-associated somatic mutations in adenomyosis

Angel Chao1,2, Ren-Chin Wu3, Chiao-Yun Lin1,2

  • 1Department of Obstetrics and Gynaecology, Linkou Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan.

Insights

This study identified key gene mutations, including KRAS and ARID1A, in adenomyosis tissue using next-generation sequencing. These findings suggest potential new targets for understanding and managing adenomyosis.

Area of Science:

  • Gynecologic Oncology
  • Molecular Pathology
  • Genetics

Background:

  • Adenomyosis pathogenesis is not fully understood.
  • Next-generation sequencing (NGS) aids in identifying causative genes and therapeutic targets.
  • Previous research noted KRAS mutations in adenomyosis.

Purpose of the Study:

  • To investigate somatic mutations in adenomyosis using a comprehensive NGS panel.
  • To identify frequently mutated genes and novel pathogenic mutations in adenomyosis.
  • To explore the role of genetic mutations in adenomyosis development.

Main Methods:

  • Somatic mutation profiling of 275 cancer susceptibility genes via NGS.
  • Analysis of adenomyotic tissue from 17 women.
  • Targeted enrichment of DNA from formalin-fixed paraffin-embedded tissue cores.

Main Results:

  • KRAS (24%) and ARID1A (12%) were the most frequently mutated genes.
  • Novel potentially pathogenic mutations were found in FBXW7 and STAG2 genes.
  • No mutations were observed in adenomyotic areas associated with endometrial atypical hyperplasia.

Conclusions:

  • Mutations in KRAS, ARID1A, FBXW7, and STAG2 likely play a role in adenomyosis pathogenesis.
  • These genetic alterations may serve as biomarkers for adenomyosis surveillance.
  • Further research is needed to validate the clinical utility of these findings.

Related Concept Videos